USFDA issues 6 observations for Piramal Pharma Turbhe facility

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-02-19 07:00 GMT   |   Update On 2025-02-19 07:00 GMT

Mumbai: Piramal Pharma has announced that the Company has received six observations from US Food and Drug Administration (USFDA) at the conclusion of the inspection at the Turbhe facility.

The US FDA conducted General GMP inspection from 11th February, 2025 to 17th February, 2025.
"On conclusion of the inspection, a Form-483 was issued with 6 observations. Observations are largely around improvement of procedures and practices and not related to data integrity," the Company stated.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

"The Company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines. The Company remains committed to maintain a highest standards of compliance and is confident of effective closure of observations," Piramal Pharma said in a BSE filing.

Read also: Piramal Critical Care launches Chlorpromazine Hydrochloride for Injection in US

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.

PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies.

In addition, PPL has a joint venture with Allergan. In October 2020, the company received a growth equity investment from the Carlyle Group.

Read also: Piramal Pharma Reports Over Fourfold Surge in Q2 Net Profit to Rs 23 Crore, Announces Expansion Plans

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News